The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Coffee and tea consumption and the risk of Parkinson's disease
Abstract
Several prospective studies have assessed the association between coffee consumption and Parkinson's disease (PD) risk, but the results are inconsistent. We examined the association of coffee and tea consumption with the risk of incident PD among 29,335 Finnish subjects aged 25 to 74 years without a history of PD at baseline. During a mean follow‐up of 12.9 years, 102 men and 98 women developed an incident PD. The multivariate‐adjusted (age, body mass index, systolic blood pressure, total cholesterol, education, leisure‐time physical activity, smoking, alcohol and tea consumption, and history of diabetes) hazard ratios (HRs) of PD associated with the amount of coffee consumed daily (0, 1–4, and ≥5 cups) were 1.00, 0.55, and 0.41 (P for trend = 0.063) in men, 1.00, 0.50, and 0.39 (P for trend = 0.073) in women, and 1.00, 0.53, and 0.40 (P for trend = 0.005) in men and women combined (adjusted also for sex), respectively. In both sexes combined, the multivariate‐adjusted HRs of PD for subjects drinking ≥3 cups of tea daily compared with tea nondrinkers was 0.41 (95% CI 0.20–0.83). These results suggest that coffee drinking is associated with a lower risk of PD. More tea drinking is associated with a lower risk of PD. © 2007 Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
(1970) · Cited by 24,983
Heart Rate Variability: Standards of Measurement, Physiological Interpretation, and Clinical Use
Electrophysiology, T. F. O. T. E. S. O. C. T. N. A. (1996) · Circulation · doi:10.1161/01.cir.93.5.1043 · Cited by 17,159
Heart rate variability: Standards of measurement, physiological interpretation, and clinical use
Malik, M., Bigger, J. T., Camm, A. J., Kleiger, R. E., Malliani, A., Moss, A. J., & Schwartz, P. J. (1996) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a014868 · Cited by 15,289
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
STAI manual for the State-trait anxiety inventory
Cd, S. (1970) · Medical Entomology and Zoology · Cited by 2,433
Wiklund, R. A., & Rosenbaum, S. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710163371606 · Cited by 2,149
Lang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391506 · Cited by 1,994
Nehlig, A., Daval, J.-L., & Debry, G. (1992) · Brain Research Reviews · doi:10.1016/0165-0173(92)90012-b · Cited by 1,461
Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase
Chiba, K., Trevor, A., & Castagnoli, N. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(84)91293-2 · Cited by 1,097
Cited by
The epidemiology of Parkinson's disease: risk factors and prevention
Ascherio, A., & Schwarzschild, M. A. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30230-7 · Cited by 1,825
Epidemiology and etiology of Parkinson's disease: a review of the evidence
Wirdefeldt, K., Adami, H.-O., Cole, P., Trichopoulos, D., & Mandel, J. (2011) · European Journal of Epidemiology · doi:10.1007/s10654-011-9581-6 · Cited by 1,199
Coffee and its Consumption: Benefits and Risks
Butt, M. S., & Sultan, M. T. (2011) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408390903586412 · Cited by 612
Maiti, P., Manna, J., & Dunbar, G. L. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0099-z · Cited by 525
Midlife Coffee and Tea Drinking and the Risk of Late-Life Dementia: A Population-Based CAIDE Study
Eskelinen, M. H., Ngandu, T., Tuomilehto, J., Soininen, H., & Kivipelto, M. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-0920 · Cited by 428
Self-citationNatural and synthetic antioxidants: An updated overview
Augustyniak, A., Bartosz, G., Čipak, A., Duburs, G., Horáková, L., Łuczaj, W., Majekova, M., Odysseos, A. D., Rackova, L., Skrzydlewska, E., et al. (2010) · Free Radical Research · doi:10.3109/10715762.2010.508495 · Cited by 319
Genetics, environmental factors and the emerging role of epigenetics in neurodegenerative diseases
Migliore, L., & Coppedè, F. (2009) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2008.10.011 · Cited by 317
Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG)
Singh, N. A., Mandal, A. K. A., & Khan, Z. A. (2015) · Nutrition Journal · doi:10.1186/s12937-016-0179-4 · Cited by 314
The neuroprotective effects of caffeine in neurodegenerative diseases
Kolahdouzan, M., & Hamadeh, M. J. (2017) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12684 · Cited by 302
Integrating Pathways of Parkinson's Disease in a Molecular Interaction Map
Fujita, K. A., Ostaszewski, M., Matsuoka, Y., Ghosh, S., Glaab, E., Trefois, C., Crespo, I., Perumal, T. M., Jurkowski, W., Antony, P. M. A., et al. (2014) · Molecular Neurobiology · doi:10.1007/s12035-013-8489-4 · Cited by 273
Caffeine and risk of Parkinson’s disease in a large cohort of men and women
Palacios, N., Gao, X., McCullough, M. L., Schwarzschild, M. A., Shah, R., Gapstur, S., & Ascherio, A. (2012) · Movement Disorders · doi:10.1002/mds.25076 · Cited by 185
Protective role of epigallocatechin-3-gallate in health and disease: A perspective
Chowdhury, A., Sarkar, J., Chakraborti, T., Pramanik, P. K., & Chakraborti, S. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.12.013 · Cited by 164
Peng, B., Yang, Q., B Joshi, R., Liu, Y., Akbar, M., Song, B.-J., Zhou, S., & Wang, X. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072316 · Cited by 156
The Effect of Caffeine on the Risk and Progression of Parkinson’s Disease: A Meta-Analysis
Hong, C. T., Chan, L., & Bai, C.-H. (2020) · Nutrients · doi:10.3390/nu12061860 · Cited by 113
Nutritional Risk Factors, Microbiota and Parkinson’s Disease: What Is the Current Evidence?
Boulos, C., Yaghi, N., El Hayeck, R., Heraoui, G. N., & Fakhoury-Sayegh, N. (2019) · Nutrients · doi:10.3390/nu11081896 · Cited by 109
Urinary N‐methylpyridinium and trigonelline as candidate dietary biomarkers of coffee consumption
Lang, R., Wahl, A., Stark, T., & Hofmann, T. (2011) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201000656 · Cited by 90
Henríquez, G., Gomez, A., Guerrero, E., & Narayan, M. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00381 · Cited by 83
Metadata
- Authors
- Hu, G., Bidel, S., Jousilahti, P., Antikainen, R., & Tuomilehto, J.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2007-08-21
- Volume
- 22
- Issue
- 15
- Pages
- 2242-2248
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2145334223
- Cited by
- 280
- References
- 72
- FWCI
- 9.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.